.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Mallinckrodt
US Department of Justice
Dow
Chinese Patent Office
Cipla
Colorcon
Merck
Julphar
McKesson

Generated: September 22, 2017

DrugPatentWatch Database Preview

Uridine triacetate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for uridine triacetate and what is the scope of uridine triacetate freedom to operate?

Uridine triacetate
is the generic ingredient in two branded drugs marketed by Wellstat Therap and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Uridine triacetate has one hundred and seventy-two patent family members in twenty-one countries.

There are thirty-five drug master file entries for uridine triacetate. One supplier is listed for this compound.

Summary for Generic Name: uridine triacetate

Tradenames:2
Patents:3
Applicants:1
NDAs:2
Drug Master File Entries: see list35
Suppliers / Packagers: see list1
Bulk Api Vendors: see list48
Clinical Trials: see list62
Patent Applications: see list52
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:uridine triacetate at DailyMed

Pharmacology for Ingredient: uridine triacetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Wellstat Therap
XURIDEN
uridine triacetate
GRANULE;ORAL208169-001Sep 4, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Wellstat Therap
XURIDEN
uridine triacetate
GRANULE;ORAL208169-001Sep 4, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Wellstat Therap
XURIDEN
uridine triacetate
GRANULE;ORAL208169-001Sep 4, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: uridine triacetate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: uridine triacetate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,103,701 Method for enhancing hematopoiesis with acyl deoxyribonucleosides► Subscribe
6,344,447 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides► Subscribe
6,232,298 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis► Subscribe
6,316,426 Acylated uridine and cytidine and uses thereof► Subscribe
5,246,708 Methods for promoting wound healing with deoxyribonucleosides► Subscribe
5,736,531 Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides► Subscribe
7,166,581Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides► Subscribe
6,348,451 Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
6,919,320 Pharmaceutical compositions containing deoxyribonucleosides for wound healing► Subscribe
5,691,320 Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: uridine triacetate

Country Document Number Estimated Expiration
China1071577► Subscribe
Australia724805► Subscribe
Austria320813► Subscribe
Japan2003119152► Subscribe
Canada2100655► Subscribe
South Africa8808083► Subscribe
Hong Kong1005740► Subscribe
South Africa8900232► Subscribe
Finland91764► Subscribe
Finland893100► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Argus Health
Moodys
Express Scripts
Healthtrust
Harvard Business School
Cipla
McKinsey
AstraZeneca
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot